A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer

NCT00626548 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
2577
Enrollment
INDUSTRY
Sponsor class

Stopped early efficacy review by the Independent Data Monitoring Committee indicated it was unlikely to meet its primary efficacy endpoints

Conditions

Interventions

Sponsor

AstraZeneca